AstraZeneca files new drug application, expanded use for another drug

WILMINGTON, Del. Anglo-Swedish drug maker AstraZeneca announced Monday that it had submitted an approval application to the Food and Drug Administration for a low-dose medication designed to reduce the risk of gastric and duodenal ulcers associated with low-dose aspirin.

The drug combines low-dose aspirin with esomeprazole, the active ingredient in the gastroesophageal reflux disease drug Nexium.

The company also submitted an application for an additional use of Nexium, also for duodenal and gastric ulcers associated with low-dose aspirin.